Harfst & Associates, Inc. Vertex Pharmaceuticals Inc Transaction History

Harfst & Associates, Inc.

$444 Million
Q3 2024

A detailed history of Harfst & Associates, Inc. transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Harfst & Associates, Inc. holds 476 shares of VRTX stock, worth $214,661. This represents 0.05% of its overall portfolio holdings.

Number of Shares

476

Previous 1,022 53.42%

Holding current value

$214,661

Previous $479,000 53.86%

% of portfolio

0.05%

Previous 0.11%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 18, 2024	SELL	$460.0 - $505.78 $251,160 - $276,155	-546 Reduced 53.42%	476 $221,000
Q1 2024 Apr 22, 2024	SELL	$407.69 - $446.08 $5,707 - $6,245	-14 Reduced 1.35%	1,022 $427,000
Q2 2023 Aug 07, 2023	SELL	$314.42 - $351.91 $369,129 - $413,142	-1,174 Reduced 53.12%	1,036 $364,000
Q1 2023 May 10, 2023	SELL	$283.23 - $323.1 $1,982 - $2,261	-7 Reduced 0.32%	2,210 $696,000
Q4 2022 Feb 13, 2023	SELL	$285.76 - $321.48 $12,287 - $13,823	-43 Reduced 1.9%	2,217 $640,000
Q3 2022 Oct 27, 2022	SELL	$273.83 - $305.53 $5,750 - $6,416	-21 Reduced 0.92%	2,260 $654,000
Q2 2022 Jul 28, 2022	SELL	$234.96 - $292.55 $5,169 - $6,436	-22 Reduced 0.96%	2,281 $642,000
Q1 2022 Apr 28, 2022	BUY	$221.42 - $260.97 $89,675 - $105,692	405 Added 21.34%	2,303 $601,000
Q4 2021 Feb 07, 2022	SELL	$177.01 - $223.45 $210,464 - $265,682	-1,189 Reduced 38.52%	1,898 $416,000
Q3 2021 Oct 28, 2021	SELL	$181.39 - $202.99 $19,771 - $22,125	-109 Reduced 3.41%	3,087 $559,000
Q2 2021 Aug 11, 2021	BUY	$187.49 - $221.1 $14,624 - $17,245	78 Added 2.5%	3,196 $644,000
Q1 2021 May 10, 2021	BUY	$207.02 - $241.31 $645,488 - $752,404	3,118 New	3,118 $670,000

Others Institutions Holding VRTX

# of Institutions

1,723

Shares Held

222M

Call Options Held

1.58M

Put Options Held

1.36M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $116B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Harfst & Associates, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Harfst & Associates, Inc. with notifications on news.

Account

Harfst & Associates, Inc. Vertex Pharmaceuticals Inc Transaction History